# Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects

> **NCT03965533** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** GSK2831781
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03965533
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2019-12-10
- **Final completion:** 2019-12-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965533, "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03965533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*